

Henry Masur

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11301077/henry-masur-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

24,367
citations

69
h-index

156
g-index

171
ext. papers

27,910
ext. citations

13.5
avg, IF

6.02
L-index

#	Paper	IF	Citations
166	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. <i>Critical Care Medicine</i> , 2021 , 49, e1063-e1143	1.4	131
165	Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. <i>Critical Care Medicine</i> , 2021 , 49, 1974-1982	1.4	31
164	Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Medicine</i> , 2021 , 47, 1181-1247	14.5	199
163	DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficient Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2021 , 73, e184-e190	11.6	5
162	Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021 , 72, S114-S120	11.6	5
161	Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8 T-Cell Function. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab118	1	0
160	Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. <i>Clinical Infectious Diseases</i> , 2021 , 72, 541-552	11.6	39
159	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. <i>American Journal of Transplantation</i> , 2021 , 21, 1780-1788	8.7	5
158	Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1614-1623	3.4	0
157	Utilization of Direct Oral Anticoagulants in People Living with Human Immunodeficiency Virus: Observational Data from the District of Columbia Cohort. <i>Clinical Infectious Diseases</i> , 2020 , 71, e604-e613	11.6	5
156	The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 1598-1605	2.9	
155	Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1715-1722	11.6	43
154	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
153	Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance. <i>Journal of Infectious Diseases</i> , 2020 , 222, S119-S131	7	17
152	Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. <i>BMC Infectious Diseases</i> , 2020 , 20, 929	4	3
151	Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4- Δ and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 221, 102-109	7	3
150	Workforce, Workload, and Burnout Among Intensivists and Advanced Practice Providers: A Narrative Review. <i>Critical Care Medicine</i> , 2019 , 47, 550-557	1.4	50

149	A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). <i>Journal of Hepatology</i> , 2019 , 71, 498-504	13.4	10
148	Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients. <i>Hepatology International</i> , 2019 , 13, 270-276	8.8	11
147	Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 323-328	3.4	6
146	Critical Care Organizations: Building and Integrating Academic Programs. <i>Critical Care Medicine</i> , 2018 , 46, e334-e341	1.4	16
145	1297. Characteristics for PrEP Uptake, Retention, and Discontinuation: Data From the ANCHOR Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S396-S396	1	78
144	Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Hepatology Communications</i> , 2018 , 2, 1451-1466	6	14
143	HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis. <i>Scientific Reports</i> , 2018 , 8, 15296	4.9	23
142	No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV. <i>Journal of Infectious Diseases</i> , 2017 , 217, 47-50	7	27
141	Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. <i>Annals of Internal Medicine</i> , 2017 , 167, 311-318	8	142
140	Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. <i>Hepatology Communications</i> , 2017 , 1, 586-594	6	26
139	Drug Resistance in <i>Pneumocystis jirovecii</i> 2017 , 1147-1162		
138	Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. <i>Clinical Infectious Diseases</i> , 2016 , 62, 440-447	11.6	30
137	Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016 , 28, 1355-64	2.2	37
136	High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. <i>Hepatology International</i> , 2016 , 10, 310-9	8.8	47
135	<i>Pneumocystis jirovecii</i> Pneumonia in Human Immunodeficiency Virus Infection. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 243-56	3.9	18
134	Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 456-62	1.6	23
133	Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. <i>Clinical Infectious Diseases</i> , 2016 , 62, 280-288	11.6	41
132	Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. <i>Aids</i> , 2016 , 30, 261-6	3.5	23

131	Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. <i>Liver International</i> , 2016 , 36, 1783-1792	7.9	60
130	Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1743-51	11.6	80
129	Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. <i>Hepatology</i> , 2015 , 61, 790-801	11.2	93
128	Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. <i>Lancet Infectious Diseases</i> , 2015 , 15, 1049-1054	25.5	136
127	Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1232-9	27.4	171
126	Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. <i>PLoS ONE</i> , 2015 , 10, e0133236	3.7	25
125	Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. <i>Lancet, The</i> , 2015 , 385, 1107-13	40	131
124	Management of Opportunistic Infections Associated with Human Immunodeficiency Virus Infection 2015 , 1642-1665.e5		
123	IFNL4- α genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. <i>Journal of Infectious Diseases</i> , 2014 , 209, 1700-4	7	71
122	Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1308-11	11.6	164
121	Treatment of hepatitis C virus infection: is it time for the internist to take the reins?. <i>Annals of Internal Medicine</i> , 2014 , 161, 443-4	8	13
120	Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3352-63	15.9	148
119	The authors reply. <i>Critical Care Medicine</i> , 2014 , 42, e798-9	1.4	
118	Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. <i>Annals of Internal Medicine</i> , 2014 , 161, 634-8	8	62
117	Infections in the immunosuppressed host. <i>Annals of the American Thoracic Society</i> , 2014 , 11 Suppl 4, S211-20	1.7	16
116	Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin. <i>Open Forum Infectious Diseases</i> , 2014 , 1, 013	1	10
115	The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. <i>Critical Care Medicine</i> , 2014 , 42, 1714-21	1.4	131
114	Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 804-11	27.4	237

113	Guidelines for the prevention of intravascular catheter-related infections. <i>Clinical Infectious Diseases</i> , 2011 , 52, e162-93	11.6	1186
112	HIV-associated Pneumocystis pneumonia. <i>Proceedings of the American Thoracic Society</i> , 2011 , 8, 294-300		118
111	Pneumocystosis 2011 , 437-453		2
110	Management of Opportunistic Infections Associated with Human Immunodeficiency Virus Infection 2010 , 1855-1886		2
109	New guidelines for the management of HIV-related opportunistic infections. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 2378-80	27.4	3
108	Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 2578-85	27.4	116
107	Fighting HIV/AIDS in Washington, D.C. <i>Health Affairs</i> , 2009 , 28, 1677-87	7	54
106	Drug Resistance in Pneumocystis jirovecii 2009 , 993-1007		
105	Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <i>MMWR Recommendations and Reports</i> , 2009 , 58, 1-207; quiz CE1-4	37.3	516
104	Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. <i>Blood</i> , 2008 , 112, 287-94	2.2	208
103	Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. <i>Critical Care Medicine</i> , 2008 , 36, 1330-49	1.4	421
102	Critically Ill Immunosuppressed Host 2008 , 1111-1132		
101	A Diagnostic Approach to Pneumocystis jirovecii Pneumonia. <i>Infectious Disease and Therapy</i> , 2007 , 267-290		
100	Management of patients with HIV in the intensive care unit. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 96-102		23
99	Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2005 , 40, S131-S235	11.6	49
98	Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. <i>Journal of Clinical Investigation</i> , 2005 , 115, 2139-48	15.9	99
97	Current epidemiology of Pneumocystis pneumonia. <i>Emerging Infectious Diseases</i> , 2004 , 10, 1713-20	10.2	309
96	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Intensive Care Medicine</i> , 2004 , 30, 536-55	14.5	1144

95	Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. <i>Critical Care Medicine</i> , 2004 , 32, 858-73	1.4	4049
94	Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. <i>Blood</i> , 2004 , 103, 3282-6	2.2	44
93	Inhalational anthrax: radiologic and pathologic findings in two cases. <i>American Journal of Roentgenology</i> , 2003 , 181, 1071-8	5.4	18
92	A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. <i>Journal of Infectious Diseases</i> , 2003 , 188, 531-6	7	13
91	Guidelines for the prevention of intravascular catheter-related infections. The Hospital Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, U.S. <i>Pediatrics</i> , 2002 , 110, e51	7.4	245
90	Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing <i>Pneumocystis carinii</i> pneumonia. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 490-4	9.7	131
89	Guidelines for the Prevention of Intravascular Catheter-Related Infections. <i>Infection Control and Hospital Epidemiology</i> , 2002 , 23, 759-769	2	156
88	High prevalence of osteonecrosis of the femoral head in HIV-infected adults. <i>Annals of Internal Medicine</i> , 2002 , 137, 17-25	8	127
87	Guidelines for the Prevention of Intravascular Catheter-Related Infections. <i>Clinical Infectious Diseases</i> , 2002 , 35, 1281-1307	11.6	166
86	Guidelines for the prevention of intravascular catheter-related infections. <i>American Journal of Infection Control</i> , 2002 , 30, 476-89	3.8	192
85	Guidelines for the prevention of intravascular catheter-related infections. <i>Infection Control and Hospital Epidemiology</i> , 2002 , 23, 759-69	2	873
84	Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. <i>MMWR Recommendations and Reports</i> , 2002 , 51, 1-52	37.3	79
83	Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. <i>MMWR Recommendations and Reports</i> , 2002 , 51, 1-29	37.3	235
82	The Changing Nature of the Prevention and Management of Opportunistic Infections. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2002 , 10, 27-30		
81	Death due to bioterrorism-related inhalational anthrax: report of 2 patients. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 2554-9	27.4	123
80	Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. <i>European Journal of Immunology</i> , 2001 , 31, 1351-60	6.1	56
79	The use of oral washes to diagnose <i>Pneumocystis carinii</i> pneumonia: a blinded prospective study using a polymerase chain reaction-based detection system. <i>Journal of Infectious Diseases</i> , 2001 , 184, 1485-8	7	46
78	Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. <i>Journal of Experimental Medicine</i> , 2001 , 194, 1731-41	16.6	185

77	Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion. <i>Clinical Immunology</i> , 2001 , 99, 30-42	9	18
76	Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy 2001 , 31, 1351		1
75	Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 2000 , 342, 1416-29	59.2	189
74	Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. <i>Journal of Infectious Diseases</i> , 2000 , 182, 1063-9	7	30
73	An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. <i>Clinical Infectious Diseases</i> , 2000 , 30 Suppl 1, S15-28	11.6	9
72	Management of Opportunistic Infections 2000 , 331-369		
71	A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 647-50	5.9	14
70	Does <i>Pneumocystis carinii</i> prophylaxis still need to be lifelong?. <i>New England Journal of Medicine</i> , 1999 , 340, 1356-8	59.2	15
69	A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. <i>Journal of Infectious Diseases</i> , 1999 , 179, 849-58	7	142
68	Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. <i>Pharmacotherapy</i> , 1999 , 19, 1050-6	5.8	37
67	Development of a PCR assay for diagnosis of <i>Pneumocystis carinii</i> pneumonia based on amplification of the multicopy major surface glycoprotein gene family. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999 , 35, 27-32	2.9	33
66	<i>Pneumocystis carinii</i> dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. <i>Journal of Infectious Diseases</i> , 1999 , 180, 1969-78	7	144
65	Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. <i>Nature Medicine</i> , 1998 , 4, 852-6	50.5	103
64	Failure of co-trimoxazole in <i>Pneumocystis carinii</i> infection and mutations in dihydropteroate synthase gene. <i>Lancet, The</i> , 1998 , 351, 1631-2	40	84
63	Pneumonia in AIDS patients in the critical care unit. <i>Critical Care Clinics</i> , 1998 , 14, 135-57	4.5	3
62	Practice guidelines for evaluating new fever in critically ill adult patients. Task Force of the Society of Critical Care Medicine and the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 1998 , 26, 1042-59	11.6	111
61	Practice parameters for evaluating new fever in critically ill adult patients. Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. <i>Critical Care Medicine</i> , 1998 , 26, 392-408	1.4	129
60	Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. <i>Journal of Infectious Diseases</i> , 1997 , 175, 781-9	7	154

59	Laboratory monitoring of cytomegalovirus disease--is polymerase chain reaction the answer?. <i>Clinical Infectious Diseases</i> , 1997 , 24, 841-2	11.6	7
58	HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. <i>Nature Medicine</i> , 1997 , 3, 533-40	50.5	460
57	Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. <i>New England Journal of Medicine</i> , 1996 , 335, 1350-6	59.2	397
56	Drug interactions in patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 1996 , 23, 685-93	11.6	139
55	Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. <i>New England Journal of Medicine</i> , 1995 , 332, 567-73	59.2	382
54	USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. USPHS/IDSA Prevention of Opportunistic Infections Working Group. <i>Clinical Infectious Diseases</i> , 1995 , 21 Suppl 1, S12-31	11.6	54
53	USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: Introduction. <i>Clinical Infectious Diseases</i> , 1995 , 21, S1-S11	11.6	30
52	Interaction of <i>Pneumocystis carinii</i> dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapson). <i>Journal of Infectious Diseases</i> , 1994 , 169, 456-9	7	22
51	Prophylaxis of <i>Mycobacterium avium</i> complex bacteremia in patients with AIDS. <i>Clinical Infectious Diseases</i> , 1994 , 18 Suppl 3, S223-6	11.6	13
50	Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat <i>Pneumocystis carinii</i> pneumonia in patients with AIDS. <i>New England Journal of Medicine</i> , 1993 , 328, 1521-7	59.2	234
49	Recommendations on prophylaxis and therapy for disseminated <i>Mycobacterium avium</i> complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for <i>Mycobacterium avium</i> Complex. <i>New England Journal of Medicine</i> , 1993 , 329, 898-904	59.2	252
48	Diagnosis of <i>Pneumocystis carinii</i> pneumonia by multiple lobe, site-directed bronchoalveolar lavage with immunofluorescent monoclonal antibody staining in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis. <i>The American Review of Respiratory Disease</i> , 1993 , 147, 888-93		45
47	Prevention and treatment of pneumocystis pneumonia. <i>New England Journal of Medicine</i> , 1992 , 327, 1853-60	59.2	191
46	Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and <i>Pneumocystis carinii</i> pneumonia. <i>Chest</i> , 1992 , 102, 1730-6	5.3	57
45	Advances in the Management of Major Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. <i>Journal of Pharmacy Practice</i> , 1992 , 5, 131-142	1.3	
44	Indeterminate western blot patterns in a cohort of individuals at high risk for human immunodeficiency virus (HIV-1) exposure. <i>Journal of Clinical Immunology</i> , 1992 , 12, 185-92	5.7	13
43	A preliminary evaluation of 566C80 for the treatment of <i>Pneumocystis pneumonia</i> in patients with the acquired immunodeficiency syndrome. <i>New England Journal of Medicine</i> , 1991 , 325, 1534-8	59.2	72
42	Effect of aerosolized pentamidine prophylaxis on the diagnosis of <i>Pneumocystis carinii</i> pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. <i>The American Review of Respiratory Disease</i> , 1991 , 144, 760-4		57

41	Characterization of dihydrofolate reductase of <i>Pneumocystis carinii</i> and <i>Toxoplasma gondii</i> . <i>Experimental Parasitology</i> , 1990 , 71, 60-8	2.1	25
40	Predicting the progression to AIDS. <i>American Journal of Medicine</i> , 1990 , 89, 701-5	2.4	31
39	Prevention of <i>Pneumocystis carinii</i> pneumonia. <i>Clinical Infectious Diseases</i> , 1989 , 11 Suppl 7, S1664-8	11.6	8
38	A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). <i>Journal of Clinical Immunology</i> , 1989 , 9, 351-61	5.7	35
37	Clinical studies of <i>Pneumocystis carinii</i> and relationships to AIDS. <i>Journal of Protozoology</i> , 1989 , 36, 70-4		5
36	Ribosomal RNA Genes of <i>Pneumocystis carinii</i> . <i>Journal of Protozoology</i> , 1989 , 36, 18s-20s		6
35	Identification of Antigens Specific for <i>Pneumocystis carinii</i> . <i>Journal of Protozoology</i> , 1989 , 36, 67s-69s		3
34	Ribosomal RNA genes of <i>Pneumocystis carinii</i> . <i>Journal of Protozoology</i> , 1989 , 36, 18S-20S		18
33	CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. <i>Annals of Internal Medicine</i> , 1989 , 111, 223-31	8	353
32	Ribosomal RNA sequence shows <i>Pneumocystis carinii</i> to be a member of the fungi. <i>Nature</i> , 1988 , 334, 519-22	50.4	651
31	Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. <i>Lancet, The</i> , 1988 , 2, 1218-22	4.2	196
30	<i>Pneumocystis carinii</i> pneumonia: therapy and prophylaxis. <i>Journal of Infectious Diseases</i> , 1988 , 158, 254-9		123
29	Treatment and Prophylaxis of <i>Pneumocystis carinii</i> Pneumonia. <i>Infectious Disease Clinics of North America</i> , 1988 , 2, 419-428	6.5	9
28	Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and <i>Pneumocystis carinii</i> pneumonia. <i>The American Review of Respiratory Disease</i> , 1987 , 136, 1199-206		150
27	Trimetrexate for the treatment of <i>Pneumocystis carinii</i> pneumonia in patients with the acquired immunodeficiency syndrome. <i>New England Journal of Medicine</i> , 1987 , 317, 978-85	59.2	212
26	Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. <i>Critical Care Medicine</i> , 1987 , 15, 503-5	1.4	23
25	Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome. <i>American Journal of Medicine</i> , 1987 , 82, 456-62	2.4	57
24	Prospective evaluation of a monoclonal antibody in diagnosis of <i>Pneumocystis carinii</i> pneumonia. <i>Lancet, The</i> , 1986 , 2, 1-3	40	114

23	Indications for and diagnostic efficacy of open-lung biopsy in the patient with acquired immunodeficiency syndrome (AIDS). <i>Annals of Thoracic Surgery</i> , 1986 , 41, 307-12	2.7	21
22	Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. <i>Annals of Internal Medicine</i> , 1986 , 104, 41-4	8	110
21	Aids Case for Diagnosis, 1986 Military Medicine. <i>Military Medicine</i> , 1986 , 151, M49-M56	1.3	
20	Selection of a skin test antigen for American visceral leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 1986 , 35, 79-85	3.2	106
19	Oligoclonal immunoglobulins in patients with the acquired immunodeficiency syndrome. <i>Clinical Immunology and Immunopathology</i> , 1985 , 35, 43-6		37
18	Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. <i>American Journal of Medicine</i> , 1985 , 78, 737-41	2.4	105
17	Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. <i>American Journal of Medicine</i> , 1985 , 78, 417-22	2.4	155
16	Thoracic manifestations of the acquired immune deficiency syndrome. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1984 , 88, 654-658	1.5	19
15	Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. <i>New England Journal of Medicine</i> , 1984 , 310, 883-9	59.2	477
14	Lymphocyte-reactive antibodies in acquired immune deficiency syndrome. <i>Journal of Clinical Immunology</i> , 1984 , 4, 118-23	5.7	59
13	Ophthalmic involvement in acquired immunodeficiency syndrome. <i>Ophthalmology</i> , 1984 , 91, 1092-9	7.3	288
12	Interferon-related leukocyte inclusions in acquired immune deficiency syndrome: localization in T cells. <i>American Journal of Clinical Pathology</i> , 1984 , 81, 147-55	1.9	45
11	Kaposi's sarcoma of the head and neck in the acquired immune deficiency syndrome. <i>Otolaryngology - Head and Neck Surgery</i> , 1984 , 92, 255-60	5.5	28
10	Pharyngeal obstruction by Kaposi's sarcoma in a homosexual male with acquired immune deficiency syndrome. <i>Otolaryngology - Head and Neck Surgery</i> , 1984 , 92, 713-6	5.5	8
9	Evaluation of abdominal pain in the AIDS patient. <i>Annals of Surgery</i> , 1984 , 199, 332-9	7.8	44
8	Serum suppression of lymphocyte activation in vitro in acquired immunodeficiency disease. <i>Journal of Clinical Immunology</i> , 1983 , 3, 156-65	5.7	83
7	Unilateral Cytomegalovirus Retinochoroiditis and Bilateral Cytooid Bodies in a Bisexual Man with the Acquired Immunodeficiency Syndrome. <i>Ophthalmology</i> , 1983 , 90, 1577-1582	7.3	22
6	Multicentric Kaposi's sarcoma of the conjunctiva in a male homosexual with the acquired immunodeficiency syndrome. <i>Ophthalmology</i> , 1983 , 90, 879-84	7.3	37

5	The acquired immunodeficiency syndrome. <i>Disease-a-Month</i> , 1983 , 30, 1-48	4.4	6
4	Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. <i>New England Journal of Medicine</i> , 1983 , 309, 453-8	59.2	1453
3	Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. <i>Annals of Internal Medicine</i> , 1982 , 97, 533-9	8	133
2	An outbreak of community-acquired <i>Pneumocystis carinii</i> pneumonia: initial manifestation of cellular immune dysfunction. <i>New England Journal of Medicine</i> , 1981 , 305, 1431-8	59.2	1194
1	Human Immunodeficiency Virus-Related Opportunistic Infections in the Era of Highly Active Antiretroviral Therapy 165-186		1